Nothing Special   »   [go: up one dir, main page]

BR9915132A - Método para inibir a atividade de quinase de proteìna, compostos da fórmula i e sais farmaceuticamente aceitáveis dos mesmos, uso do mesmo, e, composição farmacêutica. - Google Patents

Método para inibir a atividade de quinase de proteìna, compostos da fórmula i e sais farmaceuticamente aceitáveis dos mesmos, uso do mesmo, e, composição farmacêutica.

Info

Publication number
BR9915132A
BR9915132A BR9915132-4A BR9915132A BR9915132A BR 9915132 A BR9915132 A BR 9915132A BR 9915132 A BR9915132 A BR 9915132A BR 9915132 A BR9915132 A BR 9915132A
Authority
BR
Brazil
Prior art keywords
protein kinase
kinase activity
compounds
formula
pharmaceutically acceptable
Prior art date
Application number
BR9915132-4A
Other languages
English (en)
Inventor
Kevin J Doyle
Paul Rafferty
Robert W Steele
David J Wilkins
Michael Hockley
Lee D Arnold
Anna M Ericsson
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR9915132A publication Critical patent/BR9915132A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"MéTODO PARA INIBIR A ATIVIDADE DE QUINASE DE PROTEìNA, COMPOSTOS DA FóRMULA I E SAIS FARMACEUTICAMENTE ACEITáVEIS DOS MESMOS, USO DO MESMO, E, COMPOSIçãO FARMACêUTICA" A invenção refere-se a certos 3-aril ou 3-heteroaril pirazóis com fusão de anel 4,5(3,4)-bicíclico, que são inibidores da atividade de quinase de proteína, dos quais alguns são compostos novos, a composições farmacêuticas contendo estes pirazóis e a processos para preparar estes pirazóis.
BR9915132-4A 1998-11-06 1999-11-04 Método para inibir a atividade de quinase de proteìna, compostos da fórmula i e sais farmaceuticamente aceitáveis dos mesmos, uso do mesmo, e, composição farmacêutica. BR9915132A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10746798P 1998-11-06 1998-11-06
PCT/US1999/026105 WO2000027822A2 (en) 1998-11-06 1999-11-04 Tricyclic pyrazole derivatives

Publications (1)

Publication Number Publication Date
BR9915132A true BR9915132A (pt) 2001-08-07

Family

ID=22316761

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915132-4A BR9915132A (pt) 1998-11-06 1999-11-04 Método para inibir a atividade de quinase de proteìna, compostos da fórmula i e sais farmaceuticamente aceitáveis dos mesmos, uso do mesmo, e, composição farmacêutica.

Country Status (19)

Country Link
EP (1) EP1127051A2 (pt)
JP (1) JP2003517447A (pt)
KR (1) KR20010086005A (pt)
CN (1) CN1335836A (pt)
AU (1) AU762992B2 (pt)
BG (1) BG105481A (pt)
BR (1) BR9915132A (pt)
CA (1) CA2350235A1 (pt)
CZ (1) CZ20011563A3 (pt)
HK (1) HK1042895A1 (pt)
HU (1) HUP0200310A3 (pt)
ID (1) ID30132A (pt)
IL (1) IL142584A0 (pt)
NO (1) NO20012219L (pt)
PL (1) PL348210A1 (pt)
SK (1) SK5282001A3 (pt)
TR (1) TR200102277T2 (pt)
WO (1) WO2000027822A2 (pt)
ZA (1) ZA200103610B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
EP2266960B1 (en) * 1999-03-26 2014-01-22 Euro-Celtique S.A. Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants
TR200103789T2 (tr) * 1999-04-06 2002-04-22 Knoll Gmbh Tirozin kinaz inhibitörleri olarak ikameli 1,4-dihidroindeno[1,2-C]pirazoller.
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
ATE456654T1 (de) 2000-04-05 2010-02-15 Zymogenetics Inc Löslicher zytokinrezeptor zalpfa11
MXPA03000458A (es) 2000-07-20 2004-06-02 Neurogen Corp Ligandos receptores de capsaicina.
JP2004506720A (ja) 2000-08-18 2004-03-04 アグーロン　ファーマシューティカルズ，インコーポレイテッド 複素環式ヒドロキシイミノフルオレン、およびプロテインキナーゼ阻害のためのこれらの使用
AU2002228849A1 (en) 2000-12-08 2002-06-18 Bristol-Myers Squibb Pharma Company Semicarbazides and their uses as cyclin dependent kinase inhibitors
MXPA04002683A (es) * 2001-09-19 2004-06-18 Pharmacia Corp Compuestos bencenosulfamida pirazolil sustituidos para el tratamiento de la inflamacion.
AR037090A1 (es) 2001-09-19 2004-10-20 Pharmacia Corp Compuestos pirazolilo sustituidos para el tratamiento de inflamaciones
DE60311567T2 (de) * 2002-02-19 2007-10-31 Pfizer Italia S.R.L. Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
EP1599202A1 (en) * 2003-02-17 2005-11-30 Pharmacia Italia S.p.A. Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7456169B2 (en) 2003-02-27 2008-11-25 Abbott Laboratories Inc. Heterocyclic kinase inhibitors
US7320986B2 (en) 2003-03-07 2008-01-22 Abbott Labortories Fused tri and tetra-cyclic pyrazole kinase inhibitors
WO2004080973A1 (en) * 2003-03-07 2004-09-23 Abbott Laboratories Fused tri and tetra-cyclic pyrazole kinase inhibitors
JP5064795B2 (ja) * 2003-04-07 2012-10-31 アジェニックス ユーエスエー インク． サイクリン依存性キナーゼの阻害剤、組成物及びそれに関連する使用
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
MXPA06010904A (es) 2004-03-24 2007-06-11 Abbott Lab Inhibidores de pirazol cinasa triciclicos.
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
DK2987796T3 (en) 2005-02-16 2018-09-17 Anacor Pharmaceuticals Inc HALOGEN-SUBSTITUTED BORONOPHTHALIDES FOR TREATING INFECTIONS
EP1968581A4 (en) * 2005-12-16 2009-05-27 Genentech Inc TETRACYCLIC KINASE INHIBITORS
WO2007078340A2 (en) 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
PT2719388T (pt) * 2006-02-16 2019-06-11 Anacor Pharmaceuticals Inc Moléculas pequenas que contêm boro como agentes antiinflamatórios
MEP43308A (en) 2006-05-09 2011-02-10 Pfizer Prod Inc Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
AU2009221793B2 (en) 2008-03-06 2015-02-19 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
EP2597089A1 (en) * 2009-10-29 2013-05-29 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
WO2011060196A1 (en) 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011116348A1 (en) 2010-03-19 2011-09-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
ES2635333T3 (es) 2010-09-07 2017-10-03 Anacor Pharmaceuticals, Inc. Derivados de benzoxaborol para tratar infecciones bacterianas
US8853207B2 (en) 2012-04-12 2014-10-07 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof
CN102675326B (zh) * 2012-04-26 2014-08-20 华东理工大学 3,4-二氢苯并吡喃[3,4-c]吡唑类三环化合物的制备方法
WO2014039831A1 (en) * 2012-09-07 2014-03-13 Takeda Pharmaceutical Company Limited SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES
WO2015007682A1 (en) * 2013-07-15 2015-01-22 Basf Se Pesticide compounds
WO2016113261A1 (en) * 2015-01-13 2016-07-21 Basf Se Fused tricyclic compounds, compositions comprising these compounds and their use for con-trolling invertebrate pests
CN105884828A (zh) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
CN110234633A (zh) 2016-09-02 2019-09-13 百时美施贵宝公司 取代的三环杂环化合物
EP3544973B1 (en) 2016-11-28 2021-07-28 Sumitomo Chemical Company, Limited Tetrazolinone compounds and its use as pest control agents
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company OXIME ETHER COMPOUNDS
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
WO2021115560A1 (en) * 2019-12-09 2021-06-17 Rottapharm Biotech S.R.L. New fyn and vegfr2 kinase inhibitors
CN113773258B (zh) * 2020-06-09 2023-08-25 兰州大学 人源lrrk2蛋白小分子抑制剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843665A (en) * 1973-04-11 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
JPS60130521A (ja) * 1983-12-19 1985-07-12 Morishita Seiyaku Kk 抗癌剤
HUP9802319A3 (en) * 1995-10-23 1999-12-28 Zymogenetics Inc Seattle Pharmaceutical compositions for treatment of bone deficit conditions
DK1023063T3 (da) * 1997-10-06 2004-01-26 Abbott Gmbh & Co Kg Indeno[1,2-c]-,naphtho[1,2-c]- og benzo[6,7]cyclohepta[1,2-c]pyrazolderivater
WO1999017770A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity

Also Published As

Publication number Publication date
CZ20011563A3 (cs) 2003-02-12
CN1335836A (zh) 2002-02-13
TR200102277T2 (tr) 2002-01-21
ZA200103610B (en) 2002-09-23
EP1127051A2 (en) 2001-08-29
ID30132A (id) 2001-11-08
BG105481A (en) 2001-12-29
WO2000027822A3 (en) 2000-08-10
IL142584A0 (en) 2002-03-10
WO2000027822A2 (en) 2000-05-18
HUP0200310A3 (en) 2002-12-28
JP2003517447A (ja) 2003-05-27
HUP0200310A2 (hu) 2002-11-28
AU762992B2 (en) 2003-07-10
HK1042895A1 (zh) 2002-08-30
KR20010086005A (ko) 2001-09-07
NO20012219D0 (no) 2001-05-04
NO20012219L (no) 2001-06-13
PL348210A1 (en) 2002-05-06
AU1909100A (en) 2000-05-29
SK5282001A3 (en) 2002-01-07
CA2350235A1 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
BR9915132A (pt) Método para inibir a atividade de quinase de proteìna, compostos da fórmula i e sais farmaceuticamente aceitáveis dos mesmos, uso do mesmo, e, composição farmacêutica.
BR9911013A (pt) Derivados de pirazol como inibidores da p-38 map quinase
BR0014225A (pt) Derivados de pirazol
BR0312464A (pt) Inibidores de tirosina quinases
DE69725608D1 (de) Indolin-2-one derivate, verfahren zu ihrer herstellung und dieseenthaltende arzneimittel
SK157899A3 (en) Substituted pyrazoles as p38 kinase inhibitors, process for their preparation and pharmaceutical compositions
BR9303993A (pt) Composto, processo para preparar o mesmo e composição farmacêutica
BR9812944A (pt) Inibidores bicìclicos da cinase
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR0210028A (pt) Agentes antibacterianos
BR9713280A (pt) Derivados de naftiridina
BR0007589A (pt) Inibidores da proliferação de células
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
BR0008297A (pt) Uso de 4,6-o-(benzilideno-d1) -d-glucopiranose, 4,6-o-benzilideno-l-glucopiranose, e/ou 4,6-o-(benzilideno-d1) -l-glucopiranose, ou um sal farmacêutico aceitável dos mesmos, derivado de benzaldeìdo composição farmacêutica, e, processo para a fabricação da mesma
TR200000737T2 (tr) İkame edilmiş kroman türevleri.
NO20014864D0 (no) Substituerte 1,4-dihydro-inden [1,2-C] pyrazoler som inhibitorer av tyrosin kinase
ES2171018T3 (es) Uso de agentes inmunomoduladores.
BR9705456A (pt) Compostos heterocìclicos, processo de aminometila para sua preparação e composições farmacêuticas que os contêm.
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
UY26971A1 (es) Nuevos antagonistas de neuroquinina, procedimiento para su preparación y composiciones farmacéuticas que contienen estos compuestos
ES2184285T3 (es) Compuestos farmaceuticos que contienen diclorhidrato de cinconina.
DK0815109T3 (da) Fremgangsmåde til fremstilling af estere af anhydroecgonin

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ABBOTT GMBH & CO. KG (DE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.